In KAT6A‐amplified ER+/HER2− breast cancer cell lines, including ZR‐75‐1 and CAMA‐1, ISM5043 demonstrated dose‐dependent antitumor efficacy as monotherapy, which correlated with the suppression of H3K23Ac and ERα protein levels. This evidence concerns the gene KAT6A and breast carcinoma.